Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17415969 | 0.92 | ALDH1A1 (0.62) | ALDH1A1PAOXGAAAPPLMNA | |
| SCHEMBL25292439 | 0.87 | ALDH1A1 (0.50) | ALDH1A1PAOXGAAAPPLMNA | |
| SCHEMBL20589935 | 0.86 | EPHX1 (0.55) | EPHX1DRD2DRD4DRD3KDM5A | |
| SCHEMBL28075681 | 0.84 | DRD2 (0.55) | ALDH1A1PAOXAPPEPHX1DRD2 | |
| SCHEMBL28551495 | 0.84 | KDM4E (0.64) | ALDH1A1PAOXGAAAPPLMNA | |
| SCHEMBL18572992 | 0.84 | KDM4E (0.64) | ALDH1A1PAOXGAAAPPLMNA | |
| SCHEMBL11700565 | 0.83 | KDM5A (0.47) | ALDH1A1PAOXLMNAEPHX1KDM5A | |
| SCHEMBL2835194 | 0.83 | ALDH1A1 (0.49) | ALDH1A1LMNAKDM4EMAPK1KMT2A | |
| SCHEMBL27093719 | 0.80 | ALDH1A1 (0.47) | ALDH1A1PAOXGAALMNAKDM4E | |
| SCHEMBL6993648 | 0.78 | GAA (0.56) | ALDH1A1PAOXGAALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036487-A1 | Combinations | PFIZER INC. | 2009-02-05 | — | — | US | claimed |
| EP-1667722-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | Pfizer Limited (GB) | 2006-06-14 | — | — | EP | claimed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | claimed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | claimed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-2968220-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| EP-2533645-B1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2968220-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Agenebio, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-1750724-A4 | METHOD FOR IMPROVING COGNITIVE FUNCTION BY CO-ADMINISTRATION OF A GABAB RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | UNIV JOHNS HOPKINS (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1750724-A1 | METHOD FOR IMPROVING COGNITIVE FUNCTION BY CO-ADMINISTRATION OF A GABAB RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1667722-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | Pfizer Limited (GB) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005112946-A1 | METHOD FOR IMPROVING COGNITIVE FUNCTION BY CO-ADMINISTRATION OF A GABAB RECEPTOR ANTAGONIST AND AN ACETYLCHOLINESTERASE INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267077-A1 | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor | JOHNS HOPKINS UNIVERSITY (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065176-A1 | Combinations | FIELD MARK JOHN (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036487-A1 | Combinations | CHRNE, CHRND, CHRNG | ALDH1A1 4325/4885PAOX 3146/4885GAA 2461/4885 |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, BACE1, GRIN2A | ALDH1A1 1226/4885PAOX 4257/4885GAA 89/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | ALDH1A1 2171/4885PAOX 2049/4885GAA 1152/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | ALDH1A1 1226/4885PAOX 4257/4885GAA 89/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | ALDH1A1 2614/4885PAOX 4307/4885GAA 545/4885 |
| US-20050065176-A1 | Combinations | CHRNE, CHRND, CHRNG | ALDH1A1 4325/4885PAOX 3146/4885GAA 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.